Wasatch BioLabs’ direct Targeted Methylation Sequencing (dTMS) enables targeted sequencing at thousands of regions of interest with enrichment of 500-2,500x and depth that can be scaled according to researchers' needs. Unlike other traditional targeted sequencing assays, WBL’s technology leverages a proprietary library preparation protocol and third generation, native strand sequencing. Native sequencing preserves epigenetic base modifications, allowing researchers to acquire sequence and methylation and hydroxymethylation data in single runs with unparalleled precision and sensitivity.
This technology is currently being leveraged in research and diagnostic development within diverse therapeutic areas.
Direct, native detection bypasses the need for bisulfite conversion and PCR amplification, eliminating their associated biases and DNA damage.
WBL’s sequencing technology enables the analysis of:
dTMS leverages proprietary library preparation and hybridization-based enrichment protocols to streamline the targeted acquisition of native sequence and methylation data. WBL’s protocol bypasses the amplification and conversion steps required in traditional methylation analyses, reducing errors and biases in your data.
Tissue of Origin Identification Targeting 1,235 regions (2,000 bp each) with tissue-specific methylation patterns using 4,940 probes resulted in accurate identification and quantification of gDNA from our tissue of interest. Analysis of 2000 randomly selected reads yielded a correlation between predicted and true fractions of a dilution series of R2 = 0.999.
NGS 3.0 data with fully streamlined bioinformatics pipelines.
Results within 14-21 days of your sample’s arrival at the lab.
Teams of dedicated researchers and project managers to support your research and development.
Direct access to an online portal for sample information and batch status at each step of the sequencing process.
